The global amniotic membrane market size was estimated at USD 3.2 billion in 2022 and is estimated to grow at a compound annual growth rate (CAGR) of 13.0% from 2023 to 2030. The amnion membrane is used for wound healing due to its bacteriostatic and pain-reduction properties. Increasing awareness in the recent past has led to a rise in the number of transplants leading to increasing demand for these tissue-based products. This awareness has also led to a surge in the number of donations, thus, fueling the market growth. Typically, amniotic membranes are used for indications including reconstruction of the conjunctiva surface, pterygium excisions, surgical wounds, corneal ulcers, pressure and venous leg ulcers, limbal stem cell deficiency, and regenerative medicine among others.
Therefore, factors, such as increasing research in the field of stem cell and regenerative medicine, heavy R&D investments, and a rise in the number of surgeries performed worldwide, are expected to influence the market growth. In May 2020, scientists from the Eugenia Menni Research Centre (CREM) in Brescia, Italy demonstrated for the first time that stem cells taken from the human amniotic membrane can slow the development of scarring in pulmonary fibrosis. This pre-clinical research could lead to new remedies for this fatal condition.
The COVID-19 pandemic caused enormous disruption in the supply chain of the overall medical device industry. The pandemic considerably transformed the functioning of healthcare systems. Disruptions across supply & demand chains, production capacities, and sales and revenue cycles were observed resulting in restrictions on economic activity.
Amniotic membranes are typically used in two categories, as a surgical graft or as a biological bandage for treating and managing wounds. The usage of these membranes facilitates re-epithelization acting as a scaffold when used as a graft. In June 2021, Amniox Medical, Inc. launched an awareness campaign that highlighted its tissue-based products to minimize the cost of care related to wound healing. Its anti-inflammatory and anti-scarring properties are especially vital in case of burn injuries, reducing intensified inflammation, and discomfort in patients. Hence, increasing awareness about these benefits is anticipated to propel market growth. Moreover, they are widely used in the treatment of eye surface disorders, such as in the treatment of cataract, bacterial keratitis, corneal ulcers, glaucoma, corneal degeneration, bullous keratopathy, eyelid reconstruction, ocular dystrophy, and others. A rise in the geriatric population worldwide has spurred the number of ophthalmology surgeries, creating a huge demand for these tissue-based products. According to a report from the Centers for Disease Control and Prevention from 2019, approximately 1 million people suffer from eye infections every year.
Based on the product, the market is classified into dehydrated and cryopreserved amniotic membranes. Cryopreserved amniotic membrane held the largest revenue share of more than 50.0% in 2022 due to its high adoption and effectiveness. Dehydrated amniotic membranes are typically used for the treatment of various surgical wounds, reconstruction procedures, and venous and pressure leg ulcers.
Usually, these are used as biological bandages to promote healing. PalinGen, FlÅGraft, AmbioDisk, and AmnioFix are some examples of commercially available dehydrated amniotic membranes. In addition, these membranes are widely used in the treatment and management of surgical wounds and incisions owing to properties, such as their ability to maintain a watertight seal, inhibit inflammatory responses, and prevent disease transmissions. Thus, the rising usage of dehydrated membranes is anticipated to fuel the segment’s growth.
On the basis of application, the market is segmented into ophthalmology, surgical wounds, and others. The surgical wounds segment accounted for the maximum revenue share of 36.7% in 2022 owing to a global rise in the number of surgical procedures. In addition, these membranes are used in reconstructive surgeries to promote healing and reduce scarring. For instance, in July 2020, Merakris, a developer of wound-healing solutions for the skin and eyes, introduced a new skin-graft substitute to aid in the healing & protection of wounds. A tiny piece of human amniotic tissue from the placenta that was donated at the moment of childbirth makes up the amniotic membrane allograft tissue.
It has been utilized for the healing of surgical wounds for almost a century. The ophthalmology segment is estimated to grow at the fastest CAGR of 14.1% as these products are most often used in ophthalmic surgeries to initiate faster recovery and reduce inflammation. According to the American Society of Plastic Surgeons, in 2017, around 17.5 million surgical cosmetic surgeries were performed across the U.S. These facts are indicative of the rising number of individuals undergoing surgery to enhance their aesthetic appeal.
Based on end-use, the market is segmented into hospitals, ambulatory surgical centers (ASCs), specialty clinics, and research & academic institutes. The hospital segment held the largest share of 38.4% in 2022. This is mainly due to frequent visits by patients as hospitals are the primary care settings facilitating easy treatment for a wide range of diseases. The ASCs segment is expected to grow at the fastest CAGR of 13.2% from 2023 to 2030 due to the rising usage of amniotic membranes in these centers, which is expected to enhance market growth. The use of these products is easy and effective and also facilitates recovery of the wound without frequent visits to ASCs. As per the data from SurgeryView product (Definitive Healthcare), there were over 11,800 operative ASCs across the U.S. in 2022.
Specialty clinics that are taken into consideration in the study are burn centers, plastic surgery clinics, dermatology clinics, and others. As most of these require methods to prevent infections and promote effective wound healing, the use of amniotic membranes is frequently seen in these settings, facilitating segment growth. Research and academic institutes also hold a significant share of the global market owing to increasing R&D investments by major market players and hospitals to understand the possible applications of the products. The amniotic membrane provides a substrate for stem cells that can be used in various other applications, propelling increasing research on the subject.
North America dominated the market in 2022 with a revenue share of 31.7%. Well-established healthcare facilities and the presence of leading market players in North America are the major factors responsible for regional market growth. Increased focus on alternative technologies along with the adoption of advanced technologies in this region is expected to boost the market growth during the forecast period. Europe accounted for the second-highest revenue share of 27.4% and is expected to grow at a CAGR of 12.6% over the forecast period. The healthcare system in Europe is publicly funded and some countries have adopted universal healthcare systems, thereby increasing the product demand. A rising number of patients suffering from chronic diseases is expected to boost the adoption of amniotic membranes among healthcare professionals.
According to the WHO, non-communicable diseases, such as cardiovascular diseases, chronic respiratory diseases, diabetes, and cancer, together account for over 86% of deaths and 77% of the disease burden in Europe. Thus, a high prevalence of chronic diseases and a rise in surgical interventions are anticipated to accelerate market growth. Asia Pacific is predicted to grow at the fastest CAGR of 14.5% over the forecast period. Most of the countries in this region are developing economically and the disposable income is steadily increasing. Several multinational companies are heavily investing in this region. In addition, large unmet needs along with developing healthcare infrastructure, especially in Japan and India, are the major factors anticipated to enhance the market growth.
The market constitutes a large number of global as well as local players. The majority of the players have strong collaborations with tissue banks and hospitals to ensure placental donations. Almost all of the key players are accredited by the American Association of Tissue Banks (AATB) to provide quality and sterile products. These factors are anticipated to aid in the growth of the market during the forecast period. Moreover, key players are mainly involved in developing and marketing membranes solely focused on specific areas of application. For instance, AmnioFix, developed by MiMedx Group Inc., is a dehydrated amniotic membrane that is used particularly for surgical incisions as it acts as a barrier membrane and reduces scar tissue formations.
In March 2022, Laboratories Thea SAS announced an agreement with Akorn Operating Company LLC to purchase seven branded ophthalmic products, including AcellFX to expand its presence in the U.S. AcellFX is an acellular amniotic membrane that provides covering for repair or a protective environment to the ocular surface. In addition, in February 2022, U.S.-based Amnio Technology launched two latest PalinGen membrane products, Dual Layer PalinGen X-Membrane & PalinGen Dual-Layer Membrane, which are, chorion-free, homologous use, and minimally manipulated.
They are indicated for complex surgical wounds, non-healing wounds, & burns. In January 2023, Celularity, a U.S.-based company that develops biomaterial products & placental-derived allogeneic cell therapies, and CH Trading Group, an international trading company, entered into a distribution agreement with a leading healthcare distributor in the Middle East, The Tamer Group. It will be an exclusive distributor of Biovance, Biovance 3L, Interfyl, and CentaFlex, i.e., branded regenerative biomaterial products of Celularity, in Saudi Arabia.Some of the key players operating in the global amniotic membrane market are:
Alliqua BioMedical Inc.
Amnio Technology, LLC
Applied Biologics LLC
Human Regenerative Technologies, LLC
Katena Products, Inc.
MiMedx Group Inc.
Skye Biologics, Inc.
Amniox Medical Inc.
Market size value in 2023
USD 3.61 billion
Revenue forecast in 2030
USD 8.50 billion
CAGR of 13.0% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million/billion, and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, application, end-use, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; Saudi Arabia; South Africa; UAE; Kuwait
Key companies profiled
Alliqua BioMedical Inc.; Amnio Technology, LLC; Applied Biologics LLC; Human Regenerative Technologies, LLC; DermaSciences, Katena Products, Inc.; MiMedx Group Inc.; Skye Biologics, Inc.; Amniox Medical Inc.; Organogensis, Inc.
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global amniotic membrane market report on the basis of product, application, end-use, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Application Outlook (Revenue, USD Million, 2018 - 2030)
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Ambulatory Surgical Centers (ASCs)
Research And Academic Institutes
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East and Africa
b. The global amniotic membrane market size was estimated at USD 3.25 billion in 2022 and is expected to reach USD 3.61 billion in 2023.
b. The global amniotic membrane market is expected to grow at a compound annual growth rate of 13.0% from 2023 to 2030 to reach USD 8.5 billion by 2030.
b. Cryopreserved amniotic membrane held the largest market share of 59.0% in 2022 owing to high effectivity and usage. Usage of these membranes in ocular surgeries facilitates faster recovery and reduced inflammation of the eye, promoting market growth.
b. Major market players included in the amniotic membrane market are Alliqua BioMedical, Inc.; Amnio Technology, LLC; Applied Biologics LLC; Human Regenerative Technologies, LLC; DermaSciences; Katena Products, Inc.; MiMedx Group, Inc.; Skye Biologics, Inc.; Amniox Medical, Inc.; and Organogensis, Inc.
b. Key factors that are driving growth are rising awareness regarding transplants leading to a rise in the number of transplants due to increasing demand for tissue-based products. It has also led to a rise in the number of donations thus, fueling the market growth.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."